Dimensional Fund Advisors LP reduced its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 13.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,642,281 shares of the company’s stock after selling 412,982 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Myriad Genetics were worth $121,546,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP purchased a new position in shares of Myriad Genetics in the 3rd quarter valued at approximately $130,000. Royal Bank of Canada grew its stake in shares of Myriad Genetics by 59.5% in the 1st quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock valued at $136,000 after purchasing an additional 1,715 shares during the last quarter. Robecosam AG grew its stake in shares of Myriad Genetics by 39.8% in the 2nd quarter. Robecosam AG now owns 4,193 shares of the company’s stock valued at $156,000 after purchasing an additional 1,193 shares during the last quarter. First Quadrant L P CA purchased a new position in shares of Myriad Genetics in the 3rd quarter valued at approximately $201,000. Finally, Parametrica Management Ltd purchased a new position in shares of Myriad Genetics in the 3rd quarter valued at approximately $204,000. Institutional investors own 99.80% of the company’s stock.
Myriad Genetics stock opened at $31.51 on Friday. The company has a current ratio of 3.17, a quick ratio of 2.83 and a debt-to-equity ratio of 0.23. Myriad Genetics, Inc. has a 1-year low of $27.27 and a 1-year high of $50.44. The company has a market capitalization of $2.36 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 1.83 and a beta of 0.36.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $0.43 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.13. Myriad Genetics had a return on equity of 10.07% and a net margin of 7.07%. The firm had revenue of $202.30 million for the quarter, compared to the consensus estimate of $203.20 million. During the same period in the previous year, the business earned $0.26 earnings per share. The company’s revenue for the quarter was up 13.1% compared to the same quarter last year. On average, equities analysts anticipate that Myriad Genetics, Inc. will post 1.5 earnings per share for the current fiscal year.
Several brokerages have weighed in on MYGN. Morgan Stanley lifted their target price on Myriad Genetics from $47.00 to $49.00 and gave the company an “overweight” rating in a research note on Wednesday, August 22nd. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a research note on Tuesday, October 23rd. Barclays decreased their price target on Myriad Genetics from $30.00 to $25.00 and set an “underweight” rating on the stock in a research note on Tuesday, September 11th. BidaskClub downgraded Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 21st. Finally, Stephens lifted their price target on Myriad Genetics from $45.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $41.90.
ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Has $121.55 Million Holdings in Myriad Genetics, Inc. (MYGN)” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2018/12/08/dimensional-fund-advisors-lp-has-121-55-million-holdings-in-myriad-genetics-inc-mygn.html.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Featured Story: Consumer Price Index (CPI)
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.